SCHEMBL14484644

SCHEMBL14484644

O=C(O)Cc1c[nH]c2cc(F)c(F)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.67
GPR84 Q9NQS5 2/20 0.62
ALDH1A1 P00352 3/20 0.59
HPGD P15428 3/20 0.59
LMNA P02545 2/20 0.59
GLA P06280 1/20 0.59
CYP2C9 P11712 1/20 0.59
NFKB1 P19838 1/20 0.59
PMP22 Q01453 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
KDM4E B2RXH2 3/20 0.54
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44
DNMT1 P26358 1/20 0.44
RECQL P46063 1/20 0.44
CASP6 P55212 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651073 1.00 TSHR (0.67) TSHRGPR84ALDH1A1HPGDLMNA
SCHEMBL6327060 0.85 GPR84 (0.61) TSHRGPR84ALDH1A1HPGDLMNA
SCHEMBL31291665 0.84 HTR2B (0.64) TSHRGPR84ALDH1A1HPGDLMNA
SCHEMBL14487976 0.81 GPR84 (0.56) TSHRGPR84ALDH1A1HPGDLMNA
SCHEMBL22678670 0.81 ALDH1A1 (0.66) TSHRALDH1A1HPGDLMNAGLA
SCHEMBL4098433 0.80 TSHR (0.77) TSHRGPR84ALDH1A1HPGDLMNA
SCHEMBL2260803 0.80 TSHR (1.00) TSHRGPR84ALDH1A1HPGDLMNA
SCHEMBL29651210 0.80 TSHR (0.77) TSHRGPR84ALDH1A1HPGDLMNA
SCHEMBL5915286 0.79 ALDH1A1 (0.59) TSHRGPR84ALDH1A1HPGDLMNA
Hydrochloric Acid SCHEMBL1372337 0.79 TSHR (0.97) TSHRGPR84ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 US disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 US disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
CN-114555585-A HPK1 inhibitors and uses thereof 上海齐鲁锐格医药研发有限公司 2022-05-27 CN disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 US disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 US disclosed
US-10370358-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2019-08-06 US disclosed
US-10370358-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2019-08-06 US disclosed
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
EP-2729448-B1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2015-09-09 EP disclosed
EP-2729448-B1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2015-09-09 EP disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed
EP-2729448-A1 COMPOUNDS FOR THE TREATMENT OF HIV Gilead Sciences, Inc. (US) 2014-05-14 EP disclosed
CN-103621505-A Application of halogenated indole-3-acetic acid as herbicide UNIV SOUTHEAST 2014-03-12 CN disclosed
WO-2013006738-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2013-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370358-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN TSHR 4824/4885GPR84 2464/4885ALDH1A1 649/4885
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 TSHR 1352/4885GPR84 1636/4885ALDH1A1 3619/4885
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 TSHR 4690/4885GPR84 3686/4885ALDH1A1 3740/4885
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN TSHR 4824/4885GPR84 2464/4885ALDH1A1 649/4885
US-11034668-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN TSHR 4824/4885GPR84 2464/4885ALDH1A1 649/4885
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN TSHR 4824/4885GPR84 2464/4885ALDH1A1 649/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN TSHR 4824/4885GPR84 2464/4885ALDH1A1 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.